To study vascular actions of synthetic alpha-human atrial natriuretic polypeptide (alpha hANP) in man, forearm blood flow (FBF) was measured by strain-gauge plethysmograph during the continuous infusion of 100 ng/min alpha hANP dissolved in 5% dextrose into the brachial artery in healthy subjects. alpha hANP increased FBF, with the concomitant increase in ipsilateral limb venous plasma concentrations of alpha hANP. Overall, there was a significant linear correlation between the decrements of ipsilateral forearm vascular resistance (FVR) during infusions of alpha hANP and initial FVR levels (r = -0.883, P less than 0.01). Moreover, alpha hANP, at the stepwise increasing doses of 20, 100, and 500 ng/min, increased FBF in a dose-related fashion: alpha hANP elicits a concentrationdependent vasodilation of forearm vascular beds. Concomitantly, infusions of alpha hANP caused a dose-dependent increase in ipsilateral limb venous plasma cyclic guanosine monophosphate (cyclic GMP). Overall, there were direct correlations of FBF either to ipsilateral venous plasma alpha hANP (r = 0.724, P less than 0.01) or to cyclic GMP concentrations (r = 0.637, P less than 0.01). Subsequently, isoosmolar CaCl2 solution was infused into the same brachial artery at a rate of 0.09 meq/min, and then, with a 2.5 +/-0.2-mg/dl increase in ipsilateral venous serum calcium concentrations the incremental responses of both FBF and plasma cyclic GMP to alpha hANP were severely […] 
Introduction
Mammalian atrial extracts have been demonstrated to contain peptides with potent natriuretic and diuretic properties (1) (2) (3) (4) (5) .
Partial purified atrial extracts were also found to relax isolated vascular smooth muscle (4) (5) (6) . Several investigators have purified, sequenced, and synthesized atrial peptides (5, (7) (8) (9) (10) . Re- cently, the complete sequence of a-human atrial natriuretic polypeptide (ahANP)l has been obtained from purified human atrial extracts (1 1) . With the subsequent synthesis of ahANP precise investigation of the renal and vascular actions ofthis peptide in human beings has been possible. Intravenous administration of ahANP in normal subjects caused marked natriuresis and diuresis (12) (13) (14) (15) (16) (17) (18) (19) (20) . But, the vasorelaxant action of this peptide has not been defined, despite the occurrence of a mild hypotension ( 15, 16, 19) . In anesthetized rats the infusion of atrial natriuretic peptides (ANP) decreased systemic and regional vascular resistances (21, 22) , but in conscious rats and man failed to decrease these vascular resistances ( 19, 20, 23, 24) . Intravenous administration of ANP in conscious animals increased systemic and regional vascular resistances during the fall in blood pressure, possibly through reflex compensatory mechanisms, to maintain blood pressure in the face of the decreased cardiac output (23) . In the present study, therefore, we have studied the possible direct effect of ahANP on forearm vascular beds in man, by measurement of forearm blood flow (FBF) followed by the intraarterial administration of synthetic ahANP at such low doses that did not alter heart rate or systemic blood pressure. This method was chosen because it was devoid of circulatory reflexes and so enabled evaluation ofdirect pharmacological actions on the peripheral vasculature in man (25) .
It has been hypothesized that ANP-induced relaxation of vascular smooth muscle may be mediated through the formation of cyclic guanosine monophosphate (cyclic GMP) (26) . This hypothesis was based upon the observation that ANP elevated cyclic GMP levels in plasma, vascular smooth muscle, and isolated renal tubules (27) (28) (29) (30) . Such increases apparently occur through direct activation of particulate guanylate cyclase, rather than inhibition of phosphodiesterase (27, 28) . Thus, cyclic GMP may be a second messenger for this hormone (31) . It is well established that calcium ion (Ca2+) is an important regulator of hormone-sensitive adenylate cyclase and guanylate cyclase (32) . Several investigators have demonstrated that high concentration of extracellular Ca2" blunts the action of antidiuretic hormone, by inhibition of adenylate cyclase activation in the renal tubules (33) and in the toad bladder (34) . Moreover, it has been reported that high extracellular Ca2" sharply inhibits particulate guanylate cyclase activity in the heart and lung (35, 36) . Therefore, we studied the effect of increasing Ca2" concentration in forearm arterial blood on vasorelaxation and cyclic GMP formation in forearm vascular beds at several concentrations of ahANP.
Methods
All 31 subjects were healthy (5 women, 26 men), young (18-22 yr) , Japanese students at University ofTsukuba and were fully informed of the purposes, procedures, and hazards of the experiment; written consent was obtained. These volunteers were studied in the resting, postabsorptive state in an air-conditioned laboratory, with ambient temperature ranging from 240 to 270C. With the subject comfortable in the supine position and his arms supported at a 450 angle from the long axis of the body, 19-gauge hypodermic needles with attached plastic tubing were inserted in an upstream direction into an antecubital vein of one arm ("ipsilateral" arm) distal to the elbow. Under local xylocaine anesthesia the ipsilateral brachial arteries were also cannulated in an upstream direction with 20-gauge arterial needles. To improve mixing ofinfusate with brachial arterial blood ajet-injector needle was used for the intraarterial infusions. Infusion rate was 1.0 ml/min (Harvard mini-pump, Harvard Apparatus Co., Natick, MA). This jetinjection system improves mixing of infused substances with brachial arterial blood at infusate kinetic energies too low to cause significant hemolysis. The jet needle was introduced into the brachial artery through the arterial needle, an adaptor on the jet needle hub locking into the hub of the arterial needle. The tip of the jet needle usually protruded up to but not proximal to the intercondylar line at the elbow. To center the jet in the arterial lumen, the position of the jet needle was manipulated to obtain the lowest possible infusion pressure, usually not more than 200 mmHg above pressure during jet infusion into air.
FBF was measured by a plethysmographic technique, as described previously (37, 38) . Changes in forearm blood volume were determined by means of a mercury in rubber strain-gauge plethysmograph (39) placed on the midforearm. Strain-gauge was mounted so that its maximal tension was < 10 g, to prevent the gauge from obstructing even the superficial veins beneath it. To eliminate the vessels in the hand from these determinations, a sphygmomanometric cuff 7-cm wide was placed around the wrist and inflated to a level exceeding systolic arterial pressure just before each venous occlusion. A sphygmomanometric cuff 13-cm wide was placed around the upper arm, and forearm venous occlusion was produced by suddenly inflating this cuffto a pressure below the diastolic arterial pressure (40 mmHg) (40), utilizing a tank of compressed air to provide a constant pressure source. FBF was taken as the average of four to eight flow measurements made at 15-s intervals. Calculation of FBF was done independently by two of the authors from the copied records, and the average value was used for statistical analysis. The blood pressure was measured in the other arm with a sphygmomanometer. FBF, expressed as milliliters per 100 ml of forearm volume per minute, was calculated from the change in forearm circumference during venous occlusion. Forearm vascular resistance (FVR) was calculated by dividing mean arterial pressure (diastolic pressure plus one third of the pulse pressure in millimeters of mercury) by forearm blood flow (milliliters per 100 ml of forearm volume per minute); these values are expressed as "units" throughout this report. The study consisted of four interrelated protocols (Fig. 1) , each of which is described in detail below.
FBF response to ahANP infusion (protocol I; Fig. 1 ). 16 normal subjects were studied. After placing catheters and a strain-gauge plethysmograph, at least 15 min were allowed for each subject to become accustomed to the study conditions before beginning the protocol. Control solution was composed of 5% dextrose. The experimental solution containing synthetic ahANP was brought to volume with 5% dextrose. With the subject comfortable in the supine position, control solution was infused for 10 min, followed by infusions of solution containing ahANP delivered 100 ng/min into brachial arterial blood for 10 min. During the last 2 min of each infusion, FBF was measured by strain-gauge plethysmograph. Immediately before the ahANP infusion and at the end of the infusion, we sampled the ipsilateral and contralateral venous blood for the measurement of ahANP into the tube containing EDTA -2Na (1 mg/ml) and Trasylol (500 KIU/ml). FBF and plasma cyclic GMP responses to ahANP infusion and calcium effects (protocol II; Fig. 1 ). Six normal subjects were admitted to the trial. After the infusion of control solution, ahANP, at stepwise increasing rates of 20, 100, and 500 ng/min, was infused into brachial arterial blood for each 10 min. Subsequently, control solution was again infused for 10 min, and then isoosmolar CaCl2 solution was infused into brachial arterial blood at a rate of0.09 meq/min for 10 min, followed by infusions of the mixed solutions containing 20 ng/min ahANP and 0.09 meq/min CaCl2 delivered into brachial arterial blood, 100 ng/min ahANP and 0.09 meq/min CaCl2, and 500 ng/min ahANP and 0.09 meq/min CaCl2, respectively. The effect of each infusion of ahANP was compared with forearm hemodynamics measured during a preceding paired infusion of control or CaCl2 solution. As described in protocol I, at each infusion FBF was measured and venous sampling for measurements of calcium, ahANP and cyclic GMP was performed. Plasma samples for the measurement of cyclic GMP were taken with EDTA 2K (1 mg/ml).
Effects of local calcium infusion on FBF and plasma cyclic GMP responses to ahANP (protocol III; Fig. 1 ). Five normal subjects were studied. To examine whether the vascular responses to ahANP can be restored to normal after the discontinuation of CaCl2 infusion, the following study was performed. The control solution was infused for 10 min, followed by the infusion of the solution which contains ahANP delivered 50 ng/min into brachial arterial blood. After the infusion of this solution, control solution was infused for 10 min.; and then isoosmolar CaCl2 solution was infused into brachial arterial blood at a rate of 0.09 meq/min for 10 min, followed by the infusion of the mixed solution containing CaCI2 and ahANP delivered 0.09 meq/min and 50 ng/min into brachial arterial blood for each 10 min, respectively. Thereafter, control solution was again infused for 10 min, followed by the infusion of ahANP without CaCI2 delivered 50 ng/min into brachial arterial blood. The effect of each ahANP infusion was compared with hemodynamics measured during a preceding paired infusion. As described in protocol I, at each infusion FBF was measured and venous sampling for measurements of calcium and cyclic GMP was performed.
Effects of local calcium infusion on FBF and plasma cyclic GMP concentrations (protocol IV; Fig. 1 ). Four normal subjects were studied.
To examine the effect of high Ca2' on FBF and plasma cyclic GMP, isosmolar CaCl2 was infused into brachial arterial blood at a rate of 0.09 meq/min for 20 min. FBF was measured immediately before the infusion of CaC12, at 5, 10 and 20 min ofCaCI2 infusion, and at 10 min after switching it to the infusion of 5% dextrose. Venous sampling for measurement for cyclic GMP was performed before, at 10 and 20 min during, and at 10 min after the infusion of CaCl2.
Analytical methods. Serum calcium was measured by autoanalyzer. Plasma cyclic GMP was measured by radioimmunoassay (41). Radioimmunoassays of cyclic GMP were done in duplicate after succinylation. Plasma ahANP concentration was determined by radioimmunoassay, as described previously (42) . Briefly, radioimmunoassay of ahANP was performed using an antibody generated in NZW rabbits immunized with ahANP conjugated with bovine thyroglobulin. The standard buffer was 0.05 M sodium phosphate buffer, pH 7.4, containing 1% bovine serum albumin (BSA), 0.1% Triton X-100, 0.08 M NaCl, 0.025 M EDTA 2Na, 0.05% NaN3, and Trasylol 500 KIU/ml. '251-ahANP was used as a tracer (Amersham Japan, Tokyo, Japan) and synthetic ahANP synthesized in our laboratory (I 1) was used to construct standard curves. The standard ahANP or the unknown sample (100 ,l) was incubated with anti-ahANP antiserum diluent (500 Jl) for 12 h at 40C. Then, the tracer solution ( 18,000-20,000 cpm in 200 Ml) was added. After the incubation for 36 h at 4VC, anti-rabbit IgG goat serum diluent (200 gl) was added. After kept standing for 40 h at 4VC, the tubes were centrifuged at 2,000 X 30 min at 4VC. Using this proce- Table I . Neither control nor experimental infusions had significant effects on systemic blood pressure or heart rate in normal subjects. Infusion of 100 ng/min ahANP increased FBF from 2.61±0.25 to 4.82±0.48 ml/100 ml per min (P < 0.01, by paired t test), and decreased FVR from 36.8±3.6 to 18.4± 1.6 U (P < 0.01). Concomitantly, ipsilateral venous plasma ahANP concentrations increased from 106±14 to 649±54 pg/ml (P < 0.01), without a significant change in contralateral venous plasma ahANP (107±18 vs. 101 ± 13 pg/ml, NS). During infusions of ahANP, systemic blood pressure and heart rate remained unchanged. In all 16 subjects, there was a significant linear correlation between the decrements in FVR during infusions of 100 ng/min ahANP and initial FVR levels (r = -0.883, P < 0.01) (Fig. 2 ).
FBF and plasma cyclic GMP responses to ahANP infusion and calcium effects. Infusions of 20, 100, and 500 ng/min ahANP increased FBF from 239±0.35 to 3.05±0.33 (NS), 5.23±0.60 (P < 0.01) and 6.24±0.64 (P < 0.01) ml/100 ml per min, respectively (Table II) U, respectively (Table II) . Thus, ahANP elicits a concentration-dependent vasodilation of forearm vascular beds. Concomitantly, ipsilateral venous plasma ahANP concentrations increased from 88±23 to 134±26 (NS), 608±48 (P < 0.01) and 7,160±1,471 (P < 0.01) pg/ml, respectively (Table II) . Overall, there was a significant positive correlation between FBF and ipsilateral venous plasma ahANP concentrations (r = 0.724, P < 0.01) (Fig. 3) . Ipsilateral venous plasma cyclic GMP increased from 3.15± 1.05 to 4.45± 1.57 (NS), 5.30±1.51 (0.05 < P < 0.1), and 8.92±3.06 (P < 0.05) pmol/ml; thus indicating that ahANP caused a dose-dependent cyclic GMP increase. Moreover, the relaxant effect ofahANP was directly correlated to ipsilateral venous plasma cyclic GMP concentrations (r = 0.637, P < 0.01) (Fig. 4) . During the intrabrachial infusion of CaCl2, FBF was depressed with the accompaning decrease in ipsilateral plasma cyclic GMP (Table II) 5 .77±1.89 pmol/ml (P < 0.05) during infusions of 20, 100, and 500 ng/min ahANP, respectively (Fig. 6) . Thus, the simultaneous infusion of CaCl2 blunted the responses ofboth FBF and plasma cyclic GMP to ahANP. The magnitude of the increases in ipsilateral venous plasma ahANP concentrations during the ahANP infusion did not differ between with and without CaCl2 (Table II) . Contralateral venous serum calcium concentrations did not change. Neither did contralateral venous plasma cyclic GMP change. Throughout the study, systemic blood pressure or heart rate did not change (Table II) . Finally, there were significant correlations of FBF either to ipsilateral venous plasma cyclic GMP concentrations during infusions of ahANP without CaCl2 or to cyclic GMP during infusions ofahANP with CaCl2 (Fig. 4) . Fig. 4 Ipsilateral Venous Plasma o hANP Figure 3 . Regression analysis between forearm blood flow (ml/100 ml per min) and ipsilateral venous plasma ahANP concentrations (pg/ml) during the infusions of ahANP at stepwise increasing doses of 20, 100, and 500 ng/min for each 10 min (r = 0.724, P < 0.01).
Effects oflocal calcium infusion on FBF and plasma cyclic GMP responses to ahANP. Infusion of 50 ng/min ahANP increased FBF from 2.89±0.75 to 4.21±0.80 ml/ 100 ml per min (P < 0.05) ( Table III) . The simultaneous infusion ofCaCl2 and ahANP caused an insignificant increase in FBF with ahANP: from 1.62±0.39 to 1.78±0.28 ml/100 ml per min (NS). After the discontinuation of CaC12 infusion, however, ahANP pro- were restored to normal. Throughout the study, systemic blood pressure and heart rate did not change. Contralateral venous plasma cyclic GMP did not change during infusions of ahANP (Table III) .
Effects oflocal calcium infusion on FBF and plasma cyclic GMP concentration. During the infusion of CaC12, FBF was significantly decreased from 3.11±0.59 to 2.27±0.52 ml/100 ml per min (NS) at 5 min of CaCl2 infusion, to 2.10±0.36 ml/100 ml/min (P < 0.05) at 10 min of the infusion, and to 2.09±0.46 ml/100 ml/min (P < 0.05) at 20 min of CaCl2 infusion (Table IV) . At 10 min after switching the CaCl2 infusion to 5% dextrose infusion, FBF restored toward normal: 2.86±0.61 ml/100 ml per min. In contrast to the CaCl2-induced decrease in FBF, plasma cyclic GMP concentrations did not change throughout the infusion of CaCl2.
Discussion
The results of the present studies indicate that in man intraarterial infusions of synthetic ahANP decrease FVR and increase FBF in a dose-related fashion. Thus, ahANP elicits a concentration-dependent vasodilation of forearm vascular beds. Previous studies showed that pronounced natriuresis and diuresis and a mild hypotension occurred when ahANP was intravenously injected in animals (1-6) and man (12) (13) (14) (15) (16) (17) (18) (19) (20) . The depressor actions of synthetic ahANP were thought to be mediated through vasodilation, since several investigators have demonstrated that ANP are potent relaxants of norepinephrine-constricted aortic-strips or are dilators of renal blood vessels in isolated perfused rat kidneys that are constricted by norepinephrine (6, 44) . However, the continuous intravenous infusion of synthetic ANP in conscious rats failed to decrease systemic and regional vascular resistances, rather accompanied by the increase in vascular resistances and the decrease in cardiac output (23, 24) , although in anesthetized rats the administration of ANP decreased systemic and regional vascular resistances (21, 22) . Thus, in conscious rats these vascular resistances were not decreased, possibly through reflex compensatory mechanisms, in order to maintain arterial pressure in the face of decreased cardiac output (23) . Similar hemodynamic changes with infusions of ahANP have been recently demonstrated in man; the intravenous infusion of ahANP decreased blood pressure, associated with a moderate decrease in renal blood flow (19, 20) . Because it is devoid of circulatory reflexes, in the present study ahANP was infused into the brachial artery at doses so low that they did not alter heart rate or systemic arterial pressure, and so we could evaluate direct pharmacological actions of ahANP on the forearm vascular beds in man. Thus, it suggests that ahANP elicits a pronounced vascular relaxant effect in man, which is consistent with the result of the recent study using a similar intraarterial model (45) . A significant positive linear correlation between level of initial limb vascular resistance and magnitude oflimb vascular response to vasodilator agents has been reported (25). In the present study there was a similar significant correlation between initial resistance and magnitude of dilator response to ahANP. The fact that the assumption of linearity was correct for the case of ahANP is consistent with the hypothesis that ahANP is a true vasodilator agent.
The second important observation is that intrabrachial infusion of ahANP at the stepwise increasing rates induced the dose-dependent increase in ipsilateral venous plasma cyclic GMP, indicating ahANP-dependent cellular cyclic GMP formation. In the present study, moreover, there appeared to be an intimate relationship between the increase in cyclic GMP production and the vascular relaxation induced by ahANP, since there was a significant positive correlation between FBF and ipsilateral venous plasma levels of cyclic GMP during infusions of ahANP. It is consistent with the result of in vitro studies that ahANP caused a time-dependent and concentration-dependent increase in tissue levels of cyclic GMP that corresponded with vascular relaxation in the same vascular smooth muscle of the rabbit thoracic aorta (29) . Thus, cyclic GMP is thought to mediate vascular relaxation induced by ANP (26) (27) (28) (29) (30) (31) . Furthermore, the increase in cellular cyclic GMP formation is apparently due to an ANP-induced activation of particulate guanylate cyclase rather than to an inhibition of phosphodiesterases, since ANP-induced vascular relaxation and elevation of cyclic GMP levels could be inhibited by (53) . Thus, it is possible that ahANP relax vascular smooth muscle, by inhibiting an influx of extracellular calcium rather than by the increased cyclic GMP production.
In the present study, infusion of CaCl2 alone caused vasoconstriction without changes in plasma cyclic GMP, suggesting that the mechanism for Ca2+-induced vasconstriction might not involve the vascular cyclic GMP systems. Although increased Ca2' in medium could relax arterial strips (54), intraarterial infusion of calcium produced vasoconstriction in man (55) . Regarding Ca2+-induced vasoconstriction, in the presence of circulating vasoconstrictors such as norepinephrine and angiotensin the increase in extracellular calcium concentration may augment calcium entry into cell through receptor-operated calcium channels, and thus, constricting the vascular beds by the increased intracellular calcium concentrations. Moreover, it has been demonstrated that a relatively high extracellular Ca2+ inhibits specific calcium channels in vascular smooth muscle cells, possibly by the augmented inactivation of calcium channels, and then antagonizes the inhibitory effect of the calcium antagonists, cobalt (56) and magnesium ions (57) . In this study, therefore, it is suggested that the increased Ca2+ might inhibit the ANP-dependent calcium channels, and thus attenuate the decrease in intracellular Ca2 , leading to the blunted ANP-dependent vasodilation. However, there is no evidence about Ca2+ effects on the inactivation of ANP-dependent calcium channels.
An intricate relationship between cyclic nucleotide-mediated events and changes in the activity of different Ca2+ translocating mechanisms is likely to be important in most excitatory tissues. Ca2+ regulates cyclic nucleotides metabolism in several ways, conversely cyclic nucleotides can regulate 838 calcium metabolism in either a positive or negative way (32) . Therefore, there are some possibilities that pretreatment with calcium blunted the vascular relaxant effect of ahANP, through the interaction of cyclic nucleotides and intracellular Ca2'. It should be noted, however, that in the present study modest elevations ofserum calcium could attenuate the vascular responses to ahANP, whereas most of the above-mentioned in vitro studies concerned the effects of calcium at clearly superphysiological level. Further studies are needed to clarify these issues.
In summary, synthetic ahANP was infused into the brachial arterial blood in healthy volunteers, because it was devoid of circulatory reflexes. The intrabrachial infusion of ahANP caused a dose-dependent vasodilation of forearm vascular beds, with the concomitant increase in ipsilateral venous plasma cyclic GMP concentrations. There appeared to be a significant positive linear relationship between the cyclic GMP increase and the vascular relaxation induced by ahANP. Moreover, the simultaneous infusion of CaCl2 not only inhibited the ahANP-induced vascular relaxation but also blunted the accompaning increase in cyclic GMP levels. Therefore, it is suggested that ahANP acts directly on the forearm vascular beds in man, eliciting its vascular relaxant effect, possibly by increasing cellular cyclic GMP formation. Moreover, high extracellular calcium inhibits the ahANP-induced vasodilation, possibly through the suppression of cyclic GMP increase.
